NEUROCRINE BIOSCIENCES INC's ticker is NBIX and the CUSIP is 64125C109. A total of 444 filers reported holding NEUROCRINE BIOSCIENCES INC in Q2 2023. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Birchview Capital, LP | 84,240 | $7,943,832 | 5.95% |
| Prosight Management, LP | 340,000 | $32,062,000 | 4.80% |
| Logos Global Management LP | 300,000 | $28,290,000 | 3.85% |
| Bellevue Group AG | 2,612,800 | $246,387,040 | 3.52% |
| BRAIDWELL LP | 933,362 | $88,016,037 | 2.88% |
| Rock Springs Capital Management LP | 1,279,500 | $120,656,850 | 2.87% |
| Iron Triangle Partners LP | 196,000 | $18,482,800 | 2.47% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,209,714 | $114,076,030 | 2.44% |
| Parkman Healthcare Partners LLC | 139,735 | $13,177,011 | 2.28% |
| ARMISTICE CAPITAL, LLC | 1,650,000 | $155,595,000 | 2.25% |
| TOBAM | 311,715 | $29,395 | 2.22% |
| Avidity Partners Management LP | 665,316 | $62,739,299 | 2.19% |
| Sarissa Capital Management LP | 231,300 | $21,811,590 | 2.17% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 68,877 | $6,490,280 | 1.98% |
| DAFNA Capital Management LLC | 74,615 | $7,036,195 | 1.92% |
| AlphaCentric Advisors LLC | 36,500 | $3,441,950 | 1.91% |
| DSM CAPITAL PARTNERS LLC | 1,060,270 | $99,983,461 | 1.62% |
| Artia Global Partners LP | 45,000 | $4,243,500 | 1.46% |
| Woodline Partners LP | 1,152,189 | $108,651,423 | 1.29% |
| AtonRa Partners | 6,855 | $646,427 | 1.00% |
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences Inc. is a biopharmaceutical company that specializes in the development of treatments for neurological and endocrine-related disorders. The company has a strong pipeline of products in various stages of development, including clinical trials.
One of the most promising products in Neurocrine's pipeline is Ingrezza, a treatment for tardive dyskinesia, a disorder characterized by involuntary movements of the face and body. Ingrezza has been approved by the FDA and is currently being marketed in the United States.
Neurocrine is also developing a number of other products, including NBI-74788, a treatment for congenital adrenal hyperplasia, a rare genetic disorder that affects the adrenal glands. The company is also working on treatments for Parkinson's disease, epilepsy, and other neurological disorders.
In addition to its strong pipeline, Neurocrine has a solid financial position, with a market capitalization of over $10 billion. The company has a strong balance sheet, with over $1 billion in cash and investments, and no debt.
Overall, Neurocrine Biosciences Inc. is a promising biopharmaceutical company with a strong pipeline of products and a solid financial position. While there are risks associated with investing in any biotech company, Neurocrine's strong track record and promising pipeline make it an attractive investment opportunity for those interested in the biotech sector.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists NEUROCRINE BIOSCIENCES INC's shareholders in Q2 2023. To view NEUROCRINE BIOSCIENCES INC's shareholder history, click here.